H. pylori eradication does not reduce paraprotein levels in monoclonal gammopathy of unknown significance (MGUS): A prospective cohort study

Annals of Hematology

Volumn 88, Issue 8, 2009, Pages 769-773

  Soler, Juan Alfonso ^a   Güell, Mercé ^b   Bricullé, Meritxell ^a   Gavarró, Antoni ^c   Roig, Imma ^a   Sanchez, Jordi ^a,d   Gisbert, Javier P ^d,e   García, Pilar ^a,d   Villoria, Albert ^a,d   Calvet, Xavier ^a,d  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Althaia   (Spain)

^c Hospital Universitari Parc Taulí   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Eradication therapy; Helicobacter pylori; Monoclonal gammopathy of unknown significance

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN M; METRONIDAZOLE; PARAPROTEIN; PROTON PUMP INHIBITOR; TETRACYCLINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; CLARITHROMYCIN; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHIES, BENIGN; PARAPROTEINS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 67649400422     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0684-4     Document Type: Article

References (20)

1. Blade J (2006) Clinical practice. Monoclonal gammopathy of undetermined significance. N Engl J Med 355:2765-2770, doi: 10.1056/NEJMcp052790
2. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ (2007) Current concepts in the management of Helicobacter pylori infection: The Maastricht III Consensus Report. Gut 56:772-781, doi: 10.1136/gut.2006.101634
3. Emilia G, Luppi M, Zucchini P, Morselli M, Potenza L, Forghieri F, Volzone F, Jovic G, Leonardi G, Donelli A, Torelli G (2007) Helicobacter pylori infection and chronic immune thrombocytopenic purpura: Long-term results of bacterium eradication and association with bacterium virulence profiles. Blood 110:3833-3841, doi: 10.1182/ blood-2006-12-063222
4. Nakamura S, Aoyagi K, Furuse M, Suekane H, Matsumoto T, Yao T, Sakai Y, Fuchigami T, Yamamoto I, Tsuneyoshi M, Fujishima M (1998) B-cell monoclonality precedes the development of gastric MALT lymphoma in Helicobacter pylori -associated chronic gastritis. Am J Pathol 152:1271-1279
5. Chen LT, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, Wang HP, Kuo SH, Sheu BS, Jan CM, Wang WM, Wang TE, Wu CW, Chen CL, Su IJ, Whang-Peng J, Cheng AL (2005) Long-term results of anti- Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst 97:1345-1353
6. Wundisch T, Thiede C, Morgner A, Dempfle A, Gunther A, Liu H, Ye H, Du MQ, Kim TD, Bayerdorffer E, Stolte M, Neubauer A (2005) Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 23:8018-8024, doi: 10.1200/JCO.2005.02.3903
7. Pizzolitto S, Camilot D, DeMaglio G, Falconieri G (2007) Russell body gastritis: Expanding the spectrum of Helicobacter pylori - related diseases? Pathol Res Pract 203:457-460, doi: 10.1016/j.prp.2007.01.009
8. Wolkersdorfer GW, Haase M, Morgner A, Baretton G, Miehlke S (2006) Monoclonal gammopathy of undetermined significance and Russell body formation in Helicobacter pylori gastritis. Helicobacter 11:506-510, doi: 10.1111/j.1523-5378.2006.00443.x
9. Tursi A, Modeo ME (2002) Monoclonal gammopathy of undetermined significance predisposing to Helicobacter pylori-related gastric mucosa-associated lymphoid tissue lymphoma. J Clin Gastroenterol 34:147-149, doi: 10.1097/00004836-200202000-00009
10. Malik AA, Ganti AK, Potti A, Levitt R, Hanley JF (2002) Role of Helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. Am J Gastroenterol 97:1371-1374, doi: 10.1111/j.1572-0241.2002.05668.x
11. Rajkumar SV, Kyle RA, Plevak MF, Murray JA, Therneau TM (2002) Helicobacter pylori infection and monoclonal gammopathy of undetermined significance. Br J Haematol 119:706-708, doi: 10.1046/ j.1365-2141.2002.03912.x
12. Papadaki HA, Pontikoglou C, Stavroulaki E, Minadakis G, Eliopoulos DA, Pyrovolaki K, Skordilis P, Eliopoulos GD (2005) High prevalence of Helicobacter pylori infection and monoclonal gammopathy of undetermined significance in patients with chronic idiopathic neutropenia. Ann Hematol 84:317-320, doi: 10.1007/s00277-004-0996-y
13. Veneri D, Franchini M, Pizzolo G (2006) Monoclonal gammopathy of undetermined significance and Helicobacter pylori infection. Ann Hematol 85:807-809, doi: 10.1007/s00277-006-0155-8
14. Kyle RA (1993) "Benign" monoclonal gammopathy - after 20 to 35 years of follow-up. Mayo Clin Proc 68:26-36
15. Dominguez-Munoz JE, Leodolter A, Sauerbruch T, Malfertheiner P (1997) A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Gut 40:459-462
16. Wohrer S, Streubel B, Bartsch R, Chott A, Raderer M (2004) Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma. Clin Cancer Res 10:7179-7181, doi: 10.1158/1078-0432.CCR-04-0803
17. Wohrer S, Troch M, Streubel B, Hoffmann M, Mullauer L, Chott A, Raderer M (2007) Pathology and clinical course of MALT lymphoma with plasmacytic differentiation. Ann Oncol 18:2020-2024, doi: 10.1093/annonc/mdm375
18. McMahon BJ, Hennessy TW, Bensler JM, Bruden DL, Parkinson AJ, Morris JM, Reasonover AL, Hurlburt DA, Bruce MG, Sacco F, Butler JC (2003) The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 139:463-469
19. Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG (2006) Helicobacter pylori and antimicrobial resistance: Molecular mechanisms and clinical implications. Lancet Infect Dis 6:699-709, doi: 10.1016/ S1473-3099(06)70627-2
20. Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP (2005) Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: A multicenter randomized trial. Am J Gastroenterol 100:1696-1701, doi: 10.1111/j.1572-0241.2005.50019.x